2019 Symposium
|
2012 Featured Talks » Targeting for Glioblastoma Patients with Cilengitide: Promises and ChallengesTargeting for Glioblastoma Patients with Cilengitide: Promises and ChallengesDavid Reardon, MD, Center for Neuro-Oncology, Dana-Farber Cancer Institute » Download Audio David Reardon is clinical director at Dana-Farber Cancer Institute's Center for Neuro-Oncology. His research interests are brain and spinal tumors, clinical trials in neuro-oncology, targeted therapies, anti-angiogenic treatments, immunotherapy, convection-enhanced delivery. His board certifications include Neuro-Oncology, Pediatric Hematology/Oncology, and he completed his fellowship at University of Michigan Hospital, MOTT Children's Hospital, Pediatric Hematology/Oncology in 1992. He completed his residency at John Hopkins Hospital, Pediatrics, in 1989 and received his MD from Tufts Medical School in 1986. |